384 related articles for article (PubMed ID: 33628205)
21. High levels of Tim-3
Zhong W; Liu X; Zhu Z; Li Q; Li K
Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
[TBL] [Abstract][Full Text] [Related]
22. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.
Aoki T; Shimada K; Sakamoto A; Sugimoto K; Morishita T; Kojima Y; Shimada S; Kato S; Iriyama C; Kuno S; Harada Y; Tomita A; Hayakawa F; Kiyoi H
Oncotarget; 2017 Feb; 8(8):13085-13098. PubMed ID: 28055963
[TBL] [Abstract][Full Text] [Related]
23. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
24. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
Varesano S; Zocchi MR; Poggi A
Front Immunol; 2018; 9():998. PubMed ID: 29867975
[TBL] [Abstract][Full Text] [Related]
25. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
27. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
28. Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.
Cioroianu AI; Stinga PI; Sticlaru L; Cioplea MD; Nichita L; Popp C; Staniceanu F
Anal Cell Pathol (Amst); 2019; 2019():8586354. PubMed ID: 31934533
[TBL] [Abstract][Full Text] [Related]
29. Macrophage infiltration in 3D cancer spheroids to recapitulate the TME and unveil interactions within cancer cells and macrophages to modulate chemotherapeutic drug efficacy.
Singh K; Gautam PK
BMC Cancer; 2023 Dec; 23(1):1201. PubMed ID: 38062442
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model.
Kuen J; Darowski D; Kluge T; Majety M
PLoS One; 2017; 12(7):e0182039. PubMed ID: 28750018
[TBL] [Abstract][Full Text] [Related]
31. Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma.
Kusowska A; Kubacz M; Krawczyk M; Slusarczyk A; Winiarska M; Bobrowicz M
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163421
[TBL] [Abstract][Full Text] [Related]
32. Targeting tumor-associated macrophages for cancer immunotherapy.
Shu Y; Cheng P
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188434. PubMed ID: 32956767
[TBL] [Abstract][Full Text] [Related]
33. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?
Epperla N; Vaughn JL; Othus M; Hallack A; Costa LJ
Cancer Med; 2020 Aug; 9(15):5519-5525. PubMed ID: 32558356
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Invasive Activity of CAF Spheroids into Three Dimensional (3D) Collagen Matrices.
Villaronga MÁ; Teijeiro SÁ; Hermida-Prado F; Garzón-Arango M; Sanz-Moreno V; García-Pedrero JM
Methods Mol Biol; 2018; 1731():145-154. PubMed ID: 29318551
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
[TBL] [Abstract][Full Text] [Related]
36. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.
Kundu M; Butti R; Panda VK; Malhotra D; Das S; Mitra T; Kapse P; Gosavi SW; Kundu GC
Mol Cancer; 2024 May; 23(1):92. PubMed ID: 38715072
[TBL] [Abstract][Full Text] [Related]
37. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
38. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.
Li YL; Shi ZH; Wang X; Gu KS; Zhai ZM
BMC Cancer; 2019 Nov; 19(1):1049. PubMed ID: 31694577
[TBL] [Abstract][Full Text] [Related]
39. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
40. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA
Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]